Skip to content Skip to footer
Subscribe Now
Viewpoints_Laura Yecies
VIEWPOINTS

PharmaShots Interview: BoneHealth Technologies’ Laura Yecies Shares Insights on OsteoBoost Vibration Belt

In a recent interview with PharmaShots, Laura Yecies, CEO of BoneHealth Technologies shared her views on OsteoBoost Vibration Belt that has been granted 'Breakthrough Device' designation by the US FDA Shots: OsteoBoost receives the US FDA's BDD to reduce the risk of osteoporosis. It uses vibration technology that delivers mechanical stimulation to the hips & spine at…
February 2, 2021

Read more

Viewpoint_Patricia_Mae_Doykos
VIEWPOINTS

PharmaShots Interview: BMS Foundation’s Patricia Mae Doykos Shares Insights on COVID Advocacy Exchange

In a recent interview with PharmaShots, Patricia Mae Doykos, Lead, Health Equity Initiative, and Director, BMS Foundation at Bristol Myers Squibb shared her views on the promotion of health equity and improvement in health outcomes of populations disproportionately affected by serious diseases and conditions. Shots: CAE is a virtual platform that convenes advocacy groups, patients, and industry to…
January 27, 2021

Read more

Viewpoint_Dr. Michael_Shepard_2021
VIEWPOINTS

PharmaShots Interview: Enosi LifeSciences’ Dr. H. Michael Shepard Shares Insights on TNF-Inhibiting Molecules

In a recent interview with PharmaShots, Dr. H. Michael Shepard CEO and Co-Founder of Enosi shared his views on the announcement that Enosi Life Sciences has filed a patent for three of its TNF-inhibiting molecules: EN1001 for autoimmune disease, along with EN2001 and EN3001 for autoimmune disease and cancer. Shots: Enosi will offer use in multiple diseases and…
January 27, 2021

Read more

Viewpoint_Jonas_Duss_2021
VIEWPOINTS

PharmaShots Interview: Kaia Health’s Jonas Duss Shares Insights on COPD Pulmonary Rehabilitation App

In a recent interview with PharmaShots, Jonas Duss, US CEO and Co-Founder at Kaia Health shared his views on the Kaia Health's COPD Pulmonary Rehabilitation App and their collaboration with Chiesi Group to commercialize the app in EU. Shots: Kaia Health signs an exclusive agreement with Chiesi Group to commercialize the Kaia Health COPD Pulmonary Rehabilitation…
January 19, 2021

Read more

Viewpoint_Kiran_Patel_2021
VIEWPOINTS

PharmaShots Interview: Janssen’s Kiran Patel Shares Insights on Amivantamab for Metastatic EGFR Exon 20+ NSCLC

In a recent interview with PharmaShots, Kiran Patel, Vice President Clinical Development, Solid Tumor Franchise at Janssen shared his views on the regulatory submission of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Shots: Janssen reported the BLA submission to the US FDA seeking approval of Amivantamab for the…
January 13, 2021

Read more

Viewpoint_Andrew_Greenspan_2021
VIEWPOINTS

PharmaShots Interview: Janssen’s Andrew Greenspan Shares Insights on the Data Presented at ACR2020

In a recent interview with PharmaShots, Andrew Greenspan, MD, VP Medical Affairs of Janssen Immunology shared his views on Janssen's commitment to advance research in rheumatic disease. Shots: Janssen presented clinical trial results in 35 abstracts featuring findings across PsA, RA, and SLE at ACR Convergence 2020 Virtual Scientific Program Sixteen abstracts focus on Tremfya in adults…
January 11, 2021

Read more

Viewpoint_Dr. Riju_Ray_2021
VIEWPOINTS

PharmaShots Interview: GSK’s Dr. Riju Ray Shares Insights on the Role of Community-Based Pulmonologists in Improving COPD Management Among PCPs

In a recent interview with PharmaShots, Dr. Riju Ray, MD, PhD, Senior Medical Lead at GSK, leading US medical affairs across asthma and COPD shared his views on how community-based pulmonologists are improving COPD management and education among referring PCPs. Shots: Pulmonologists identified 12 strong to moderate predictors of future COPD exacerbations, some of which were evaluated…
January 7, 2021

Read more

Viewpoint_Ted_Omachi_2021
VIEWPOINTS

PharmaShots Interview: Genentech’s Ted Omachi Shares Insight on the US FDA’s Approval of Xolair in Nasal polyps

In a recent interview with PharmaShots, Ted Omachi, Global Development Leader for Xolair, and Senior Medical Director of Product Development for Immunology, Genentech shared his views on the approval of Xolair in the US. Shots: The approval is based on P-III POLYP 1 & 2 trials assessing Xolair vs PBO in 138 & 127 adult patients with…
January 6, 2021

Read more

VIEWPOINTS

PharmaShots Interview: Neoleukin’s Daniel-Adriano Silva Shares Insight on Novel Protein Designed to Treat or Block SARS-COV-2

In a recent interview with PharmaShots Daniel-Adriano Silva, PhD, Co-founder and Vice President Head of Research at Neoleukin shared the significance and promise of the findings published in Science and discuss the details of its De Novo Protein Design Shots: NL-CVX1 (CTC-445.2d) demonstrated the ability to prevent infection of multiple human cell lines in vitro and to protect…
December 18, 2020

Read more

Viewpoint_Noreen_Heng_2020
VIEWPOINTS

PharmaShots Interview: Kezar’s Noreen Henig Shares Insight on Therapeutic Potential of KZR-616

In a recent interview with PharmaShots, Noreen Henig, Chief Medical Officer at Kezar Life Sciences shared information on clinical and pre-clinical data supporting the potential of KZR-616 to positively affect multiple drivers of immune-mediated diseases. Shots: The poster presented at ACR 2020 includes additional patient-weeks of safety and tolerability data compared to prior data presentations for our…
December 17, 2020

Read more

Load more